Zobrazeno 1 - 10
of 135
pro vyhledávání: '"Monica Fornier"'
Autor:
Anthony D. Elias, Alyse W. Staley, Monica Fornier, Gregory A. Vidal, Vida Alami, Sharon Sams, Nicole S. Spoelstra, Andrew Goodspeed, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin, Kathryn L. Zolman, Tessa McSpadden, Kimberly R. Jordan, Jill E. Slansky, Virginia F. Borges, Dexiang Gao, Jennifer K. Richer
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-14 (2024)
Abstract Most ER+ breast cancers (BC) express androgen receptors (AR). This randomized phase II trial of 4 months of neoadjuvant fulvestrant (Fulv) alone or with enzalutamide (Combo) assessed whether adding AR blockade to Fulv would limit residual tu
Externí odkaz:
https://doaj.org/article/564ac0eba47340f495698648097af1b7
Autor:
Shari B. Goldfarb, Victoria Blinder, Devika Gajria, Cassandra Chang, Analisa Dacunto, Jinae Park, Monica Fornier, Mario Lacouture
Publikováno v:
Cancer Research. 83:P5-08
Background: Chemotherapy induced alopecia is one of the most distressing side effects of cancer therapy since it is a constant reminder of the underlying malignancy. Anthracycline chemotherapy induces total alopecia. Although scalp cooling devices ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a51b497bc1a1658ea31e41064e1aed76
https://doi.org/10.1158/1538-7445.sabcs22-p5-08-10
https://doi.org/10.1158/1538-7445.sabcs22-p5-08-10
Autor:
Astrid Botty Van den Bruele, Tiana Le, Monica Fornier, Varadan Sevilimedu, Monica Morrow, Emanuela Ferraro, Molly P Hogan, Virgilio Sacchini, Sidra Javed-Tayyab
Publikováno v:
Breast Cancer Research and Treatment. 189:307-315
HER2 +- amplified breast cancer patients derive benefit from treatment with anti-HER2-targeted therapy. Though adjuvant treatment is based on final pathology, decisions regarding neoadjuvant chemotherapy are made in the preoperative setting with imag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d208dcd4e6b5fcdfacf159b61223d63
https://doi.org/10.1007/s10549-021-06331-3
https://doi.org/10.1007/s10549-021-06331-3
Autor:
Rui Wang, Alexia Iasonos, Joshua Z. Drago, Komal Jhaveri, Sujata Patil, Sarat Chandarlapaty, Fanni Ratzon, Neal Rosen, Payal D. Shah, Monica Fornier, Shanu Modi, Fresia Pareja, Nancy Sklarin
Publikováno v:
Clinical Cancer Research. 27:3867-3875
Purpose: Activating mutations in PIK3CA promote resistance to HER2-targeted therapy in breast cancer; however, inhibition of PI3K alone leads to escape via feedback upregulation of HER3. Combined inhibition of HER2, HER3, and PI3K overcomes this mech
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f885de3f6429058fdfa9c7a384d0bcb
https://doi.org/10.1158/1078-0432.ccr-21-0047
https://doi.org/10.1158/1078-0432.ccr-21-0047
Autor:
Anthony D. Elias, Alyse Staley, Monica Fornier, Gregory A. Vidal, Sharon Sams, Nicole Spoelstra, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Rosa I. Gallagher, Julia Wulfkuhle, Emanuel Petricoin, Kathryn Zolman, Stephanie Biller, Vida Alami, Tessa McSpadden, Virginia Borges, Lyndsey S. Crump, Dexiang Gao, Jennifer K. Richer
Publikováno v:
Cancer Research. 83:CT144-CT144
Background: Most estrogen receptor alpha positive (ER+) breast cancers (BCs) express androgen receptor (AR) protein, but its function is unclear. High AR relative to ER is associated with endocrine resistance. This randomized phase II trial of neoadj
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85340548b90a85832ba4e5ded420688f
https://doi.org/10.1158/1538-7445.am2023-ct144
https://doi.org/10.1158/1538-7445.am2023-ct144
Publikováno v:
HSS J
Background: Denosumab is approved to prevent fragility fractures in patients with osteoporosis at high risk for fracture and to prevent bone loss in patients with breast and prostate cancer who receive endocrine therapy. The antiresorptive effect of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ed657b08d16f867984a2f569941fe71
https://doi.org/10.1177/1556331621995846
https://doi.org/10.1177/1556331621995846
Autor:
Monica Fornier, Shanu Modi, Elizabeth A. Comen, Gabriela Chiosis, Tony Taldone, Komal Jhaveri, Sarhe Khoshi, W. Ma, Nagavarakishore Pillarsetty, Rui Wang, Jacqueline Bromberg, Carlos Henrique dos Anjos, Mark Dunphy, Nathan Kadija, Susan Duggan, Sujata Patil, Anna Rodina
Publikováno v:
JCO Precision Oncology. :1414-1424
PURPOSE Epichaperome network maintenance is vital to survival of tumors that express it. PU-H71 is an epichaperome inhibitor that binds to the ATP-binding site of HSP90 and has demonstrated antitumor activity in breast cancer xenograft models and cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b39a1a6cd16a16b76fc1196c015fa518
https://doi.org/10.1200/po.20.00273
https://doi.org/10.1200/po.20.00273
Autor:
Alessia Vignoli, Lorenzo Rossi, Monica Fornier, Amelia McCartney, Emanuela Risi, Leonardo Tenori, Angelo Di Leo, Claudio Luchinat, Laura Biganzoli
Publikováno v:
npj Breast Cancer, Vol 5, Iss 1, Pp 1-5 (2019)
NPJ Breast Cancer
NPJ Breast Cancer
Despite recent refinements to the 21-gene g score, allowing a better identification of patients who may derive no benefit from the addition of adjuvant chemotherapy to that of endocrine therapy, patients with early breast cancer still stand to be ove
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3af1fe1958af713834b53173e6940374
http://link.springer.com/article/10.1038/s41523-019-0123-9
http://link.springer.com/article/10.1038/s41523-019-0123-9
Autor:
ME Moynahan, Gabriela Chiosis, Monica Fornier, Tony Taldone, S. Patil, S Khoshi, W. Ma, Shanu Modi, Elizabeth A. Comen, Jason S. Lewis, J. Bromberg, Valentina Sterlin, Mark Dunphy, Larry Norton, Komal Jhaveri, Renjing Wang, Anna Rodina
Publikováno v:
Cancer Research. 79:P6-20
Background: The epichaperome is a new cancer target required for tumor survival (Joshi et al. Nature Reviews Cancer 2018). PU-H71 is a synthetic, purine scaffold epichaperome inhibitor that binds to the ATP-binding site of HSP90 specifically when HSP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7316d0d4bc2ea75ad703b3ff3d3a7242
https://doi.org/10.1158/1538-7445.sabcs18-p6-20-03
https://doi.org/10.1158/1538-7445.sabcs18-p6-20-03
Autor:
Melissa Pilewskie, Komal Jhaveri, Varadan Sevilimedu, Giacomo Montagna, Monica Morrow, Monica Fornier
Publikováno v:
Ann Surg Oncol
Neoadjuvant endocrine therapy (NET) is effective in downstaging large hormone receptor-positive (HR+) breast cancers and increasing rates of breast-conserving surgery (BCS), but data regarding nodal pathologic complete response (pCR) are sparse. We r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::169deaeb7765a5e7eee0e911e3d72575
https://europepmc.org/articles/PMC7554166/
https://europepmc.org/articles/PMC7554166/
